Dusseldorf - Delayed Quote EUR

Novartis AG (NOTA.DU)

Compare
96.80
0.00
(0.00%)
At close: January 10 at 7:31:58 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
49,940,000.00
46,660,000.00
43,461,000.00
43,974,000.00
49,898,000.00
Cost of Revenue
12,525,000.00
12,472,000.00
11,582,000.00
11,735,000.00
15,121,000.00
Gross Profit
37,415,000.00
34,188,000.00
31,879,000.00
32,239,000.00
34,777,000.00
Operating Expense
23,819,000.00
24,419,000.00
23,933,000.00
22,183,000.00
24,625,000.00
Operating Income
13,596,000.00
9,769,000.00
7,946,000.00
10,056,000.00
10,152,000.00
Net Non Operating Interest Income Expense
-609,000.00
-419,000.00
-574,000.00
-794,000.00
-812,000.00
Other Income Expense
-255,000.00
-227,000.00
-195,000.00
15,268,000.00
538,000.00
Pretax Income
12,732,000.00
9,123,000.00
7,177,000.00
24,530,000.00
9,878,000.00
Tax Provision
975,000.00
551,000.00
1,128,000.00
1,625,000.00
1,807,000.00
Net Income Common Stockholders
17,603,000.00
14,850,000.00
6,955,000.00
24,021,000.00
8,072,000.00
Diluted NI Available to Com Stockholders
17,603,000.00
14,850,000.00
6,955,000.00
24,021,000.00
8,072,000.00
Basic EPS
8.60
7.15
3.19
10.71
3.55
Diluted EPS
8.52
7.10
3.17
10.63
3.52
Basic Average Shares
2,034,794.14
2,076,794.14
2,181,000.00
2,243,000.00
2,277,000.00
Diluted Average Shares
2,051,500.00
2,092,000.00
2,197,000.00
2,260,000.00
2,296,000.00
Total Operating Income as Reported
13,596,000.00
9,769,000.00
7,946,000.00
10,056,000.00
10,152,000.00
Total Expenses
36,344,000.00
36,891,000.00
35,515,000.00
33,918,000.00
39,746,000.00
Net Income from Continuing & Discontinued Operation
17,603,000.00
14,850,000.00
6,955,000.00
24,021,000.00
8,072,000.00
Normalized Income
11,958,612.16
8,767,876.00
6,204,112.00
22,971,411.00
8,182,295.00
Interest Income
--
627,000.00
377,000.00
70,000.00
91,000.00
Interest Expense
948,000.00
855,000.00
800,000.00
787,000.00
869,000.00
Net Interest Income
-609,000.00
-419,000.00
-574,000.00
-794,000.00
-812,000.00
EBIT
13,680,000.00
9,978,000.00
7,977,000.00
25,317,000.00
10,747,000.00
EBITDA
19,709,000.00
18,255,000.00
14,682,000.00
30,914,000.00
17,211,000.00
Reconciled Cost of Revenue
12,525,000.00
12,472,000.00
11,582,000.00
11,735,000.00
15,121,000.00
Reconciled Depreciation
6,029,000.00
8,277,000.00
6,705,000.00
5,597,000.00
6,464,000.00
Net Income from Continuing Operation Net Minority Interest
11,761,000.00
8,568,000.00
6,049,000.00
22,908,000.00
8,072,000.00
Total Unusual Items Excluding Goodwill
-214,000.00
-214,000.00
-184,000.00
-69,000.00
-135,000.00
Total Unusual Items
-214,000.00
-214,000.00
-184,000.00
-69,000.00
-135,000.00
Normalized EBITDA
19,923,000.00
18,469,000.00
14,866,000.00
30,983,000.00
17,346,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-16,387.84
-14,124.00
-28,888.00
-5,589.00
-24,705.00
12/31/2020 - 7/5/2002

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PFE.SG Pfizer Inc
26.11
+0.38%
 
0R34.IL Johnson & Johnson
143.00
+0.49%
 
GLAXO.NS GlaxoSmithKline Pharmaceuticals Limited
2,190.40
-0.81%
 
PFIZER.NS Pfizer Limited
5,254.45
-1.42%
 
RHHVF Roche Holding AG
288.71
-0.44%
 
JNJ.F Johnson & Johnson
139.32
+0.66%
 
PFE.F Pfizer Inc.
26.35
+1.19%
 
LLY.F Eli Lilly and Company
774.00
+1.08%
 
PFE.NE Pfizer Inc.
12.41
-1.12%
 
SAN.PA Sanofi
95.61
-0.72%